Welcome to our dedicated page for Candel Therapeutics news (Ticker: CADL), a resource for investors and traders seeking the latest updates and insights on Candel Therapeutics stock.
Candel Therapeutics, Inc. develops clinical-stage multimodal biological immunotherapies for cancer, including off-the-shelf viral immunotherapy platforms based on genetically modified adenovirus and herpes simplex virus constructs. Company news commonly covers aglatimagene besadenovec, also called aglatne or CAN-2409, in prostate cancer and non-small cell lung cancer, and linoserpaturev, or CAN-3110, from its HSV platform in recurrent high-grade glioma.
Updates also include clinical-data presentations, FDA designations or clearances, research-and-development communications, quarterly financial results, financing activity, and Nasdaq inducement grants under the company’s equity plans.
Candel Therapeutics (Nasdaq: CADL) announced that on February 28, 2026 its Compensation Committee granted inducement stock options to one new employee to purchase 20,000 shares at an exercise price of $5.25 per share under the company's 2025 Inducement Plan.
Vesting: 25% after one year of service, then the remaining 75% vesting in 36 equal monthly installments, all subject to continued employment. The Plan was adopted on December 24, 2025 and the awards comply with Nasdaq Listing Rule 5635(c)(4).
Candel Therapeutics (Nasdaq: CADL) announced that Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO, will present at TD Cowen’s 46th Annual Health Care Conference in Boston on Tuesday, March 3, 2026, 11:50 AM - 12:20 PM ET.
A live webcast will be available via the company’s Investors > Events and Presentations page at www.candeltx.com, and a replay will be archived for up to 90 days after the session.
Candel Therapeutics (Nasdaq: CADL) priced an underwritten public offering of 18,348,624 common shares at $5.45 per share, expected to raise approximately $100 million gross. The offering is expected to close on or about Feb 23, 2026.
The company granted a 30-day underwriter option for up to 2,752,293 additional shares. Net proceeds are intended to fund launch readiness and commercial activities for CAN-2409 (aglatimagene) in localized prostate cancer, support the phase 3 NSCLC program, and for general corporate purposes.
Candel Therapeutics (Nasdaq: CADL) announced a proposed underwritten public offering of $100 million of common stock, with a 30-day underwriter option for an additional $15 million. The company intends to use net proceeds to support launch readiness and commercialization of CAN-2409 (aglatimagene) in early localized prostate cancer, fund ongoing phase 3 development in non-small cell lung cancer (NSCLC), and for general corporate purposes.
The offering is subject to market conditions and will be made under a shelf registration declared effective by the SEC on August 22, 2025. Citigroup, Cantor, and Stifel are joint bookrunners.
Candel Therapeutics (Nasdaq: CADL) announced a $100 million royalty funding agreement with RTW to support a potential U.S. launch of aglatimagene besadenovec (CAN-2409) for intermediate- to high-risk localized prostate cancer, contingent on FDA approval and customary conditions.
Funds will be available upon approval; RTW will receive a tiered single-digit percentage of U.S. annual net sales, subject to a cap. Candel expects to submit a BLA in Q4 of this year and cites pivotal phase 3 data as the rationale for commercial potential.
Candel Therapeutics (Nasdaq: CADL) announced that Dr. Francesca Barone, Chief Scientific Officer, will present and take part in panels at the 7th Annual Glioblastoma Drug Development Summit in Boston, Feb 17–19, 2026. Presentations will cover the HSV-based platform and linoserpaturev (CAN-3110) program in recurrent high-grade glioma, focusing on biomarker-driven clinical development, imaging integration, and biomarker-based enrollment strategies to inform patient stratification and response assessment.
Candel Therapeutics (Nasdaq: CADL) announced inducement stock option grants made by its Compensation Committee on January 31, 2026. One new employee received options to purchase 6,600 shares at a per-share exercise price of $5.84 under the company’s 2025 Inducement Plan.
The options vest 25% after one year of service and the remaining 75% in 36 equal monthly installments, subject to continued employment. The Plan was adopted by the board on December 24, 2025.
Candel Therapeutics (Nasdaq: CADL) will host a virtual R&D Event on December 5, 2025 from 11:00 AM–1:45 PM ET. The program includes executive presentations, scientific panels, and collaborator talks offering an extensive overview of Candel’s viral immunotherapy approach and oncology pipeline, including CAN-2409 and CAN-3110 programs.
Featured speakers include CEO Paul Peter Tak, MD, PhD, Nobel Laureate James P. Allison, Carl H. June, MD, and clinical and regulatory leads covering BLA and pre-commercialization roadmaps. Live webcast and replay will be available on the company Investors page with registration required.
Candel Therapeutics (NASDAQ: CADL) reported Q3 2025 results and corporate updates on November 13, 2025. Key clinical progress includes subgroup phase 3 data for CAN-2409 in localized prostate cancer showing improved prostate cancer-specific DFS (HR 0.62; p=0.0046), plans to submit a BLA in Q4 2026, and intent to start a pivotal phase 3 in NSCLC in Q2 2026. Updated survival data for CAN-3110 in recurrent high-grade glioma showed median OS ~11.8–12.0 months in arms A/B. Financially, the company has $87.0M cash (9/30/25) and closed a $130M term loan with $50M drawn at signing to fund operations into Q1 2027.
Candel Therapeutics (Nasdaq: CADL) will present three data sets at SITC 2025 highlighting clinical and preclinical advances in viral immunotherapies and AI‑driven design.
Key points: a Phase 3 study of CAN‑2409 in newly diagnosed, localized prostate cancer met its primary endpoint and the company plans a BLA submission in Q4 2026; Phase 2a MOFA biomarker analysis in NSCLC showed stronger immune activation and prolonged overall survival in non‑squamous vs squamous histology; an AI‑designed candidate (Alpha‑201 IL‑12/15) produced 60.0%±12.6 tumor growth suppression in an EMT6 breast cancer mouse model.